Indeed, the SU-DHL-4 DLBCL cell line, which expresses wild-type MYC and mutant BCL2 and p53, only display temporary responses to the standard of care treatment R-CHOP, but shows no regressions in xenograft experiments [39]. Here, BCL2 is linked to diffuse large B-cell lymphoma.